Short answer
CERUS CORP (CERS) filed its Q1 2026 10-Q quarterly report on Apr 30, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $54M with net income of −$2M.
Q1 2026 key financials · XBRL
- Revenue
- $54M
- Net income
- −$2M
- +78.7% YoY
- Operating margin
- -0.7%
- EPS (diluted)
- −$0.01
- +75.0% YoY
Source: XBRL data from the CERUS CORP (CERS) Q1 2026 10-Q on SEC EDGAR. USD.
CERUS CORP Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Segment or product-line performance not quantified in supplied text
- Near-term headwinds: tariffs, trade tensions, conflicts, funding uncertainty, and ongoing red-blood-cell development costs
Risk Factors
- U.S. commercialization risk: Blood-center staffing shortages may further delay INTERCEPT adoption and implementation
- Market-adoption risk: U.S. platelet shortages may reduce demand for INTERCEPT-treated products
- Regulatory risk: FDA has not granted a seven-day storage claim for INTERCEPT-treated platelets
- Customer-concentration risk: American Red Cross utilization changes may make results difficult to predict
- Funding risk: BARDA reductions or milestone disputes could suspend the U.S. red-blood-cell development program
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CERUS CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.